TL;DR — Vitamin K2 as menaquinone-7 (MK-7) is the cofactor that lets your body carboxylate — switch "on" — two proteins that manage calcium: matrix Gla protein (MGP), which keeps calcium out of arteries, and osteocalcin, which binds it into bone. The mechanism is well-established. The clinical payoff is genuinely mixed: a 3-year RCT showed improved arterial stiffness at 180 µg/day, a separate 3-year bone trial slowed BMD decline, but a third 3-year trial in osteopenic women found no BMD benefit despite confirmed target activation. Tier B — real human RCT data, inconsistent endpoints. Dose: 180 µg/day MK-7 with a fat-containing meal; reassess biomarkers at 6–12 months.
What Vitamin K2 does (and why it matters)
Vitamin K is best known for blood clotting, but its extrahepatic job is arguably more interesting for healthspanThe portion of life spent in good health, free from chronic disease or disability — distinct from lifespan (total years alive). Full glossary →. Several proteins outside the liver are inert until a vitamin-K-dependent enzyme (γ-glutamyl carboxylase) attaches carboxyl groups to their glutamate residues. Two matter here: matrix Gla protein (MGP), a potent local inhibitor of soft-tissue calcification, and osteocalcin, which anchors calcium into the bone matrix. Without enough vitamin K, both circulate in their inactive, uncarboxylated forms — and calcium is more likely to end up in arterial walls than in bone. MK-7 is the long-chain menaquinone form with a longer circulating half-life than either dietary K1 (phylloquinone) or the shorter MK-4, which is why it dominates the supplement trials.
Primary hallmarks targeted: Altered intercellular communication · Chronic inflammation
Knapen et al. 2015 (PMID 25694037, Thrombosis and Haemostasis 113(5):1135–1144): a 3-year double-blind RCT randomized 244 healthy postmenopausal women to 180 µg/day MK-7 or placebo. Carotid artery stiffness (measured by echotracking) significantly improved in the MK-7 group versus placebo, with the strongest effect in women who started with the highest baseline stiffness; inactive (dephospho-uncarboxylated) MGP fell markedly, confirming target engagement. This is real, long-duration human RCT evidence — but see Section 3 for where the bone data does not line up.
Mechanism — carboxylation as a molecular "on switch"
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| Matrix Gla protein (MGP) carboxylation | Active MGP binds hydroxyapatite crystals and inhibits arterial calcification | Altered intercellular communication |
| Osteocalcin carboxylation | Carboxylated osteocalcin binds calcium into the bone matrix | Altered intercellular communication |
| Reduced circulating inactive MGP (dp-ucMGP) | Marker of vitamin K status; falls with supplementation | Chronic inflammation (vascular) |
Schurgers et al. 2008 (PMID 18841280, Thrombosis and Haemostasis) lays out the MGP mechanism in detail: MGP is a calcification inhibitor that is functionally useless until vitamin-K-dependent carboxylation activates it, and circulating inactive MGP is a candidate biomarker of vascular vitamin K deficiency. The mechanism is not in serious dispute — the open question is whether topping up K2 in people who are not overtly deficient changes hard outcomes.
When Vitamin K2 is worth your money
MK-7 earns a place in your stack when two or more apply:
- You supplement vitamin D3 at meaningful doses (D3 raises calcium handling; K2 helps direct where that calcium goes)
- You are postmenopausal or otherwise concerned about age-related bone-density decline
- Your diet is low in fermented foods and organ meats (the main dietary menaquinone sources)
Skip or defer if you take warfarin or any vitamin-K-antagonist anticoagulant — K2 directly opposes the drug — or if you are chasing a specific, guaranteed BMD increase, which the trials do not consistently deliver.
Evidence summary — where the RCTs agree and disagree
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Knapen 2015 (PMID 25694037) | RCT, 180 µg/day MK-7 | 244 | 3 yr | ↑ carotid distensibility, ↓ inactive MGP | B |
| Knapen 2013 (PMID 23525894) | RCT, 180 µg/day MK-7 | 244 | 3 yr | Slowed BMD decline at spine + femoral neck; ↓ uncarboxylated osteocalcin | B |
| Rønn 2021 (PMID 33030563) | RCT, 375 µg/day MK-7 | 142 | 3 yr | Osteocalcin carboxylation ↑ but no BMD difference vs placebo in osteopenic women | B |
| Ma 2022 meta-analysis (PMID 36033779) | 16 RCTs | 6,425 | Mixed | Significant ↑ lumbar-spine BMD (P=0.006), but pooled MK-4 + MK-7 trials of varying quality | B |
| Geleijnse 2004 (PMID 15514282) | Prospective cohort (Rotterdam) | 4,807 | ~7–10 yr | Higher dietary menaquinone linked to ↓ CHD mortality + severe aortic calcification | C (observational) |
← Swipe for more columns →
Consensus: Tier B. The cardiovascular-surrogate signal (arterial stiffness, dp-ucMGP) is consistent and mechanistically coherent, and one long RCT supports slowed bone loss — but a separate, equally long RCT in osteopenic women found no BMD benefit despite proving the biochemistry worked. The 2022 meta-analysis leans positive for lumbar-spine BMD, but it pools high-dose pharmaceutical MK-4 (largely Japanese osteoporosis trials) with low-dose MK-7, so it is not clean evidence for the 180 µg MK-7 supplement most people take. No trial has yet shown MK-7 reduces fractures or cardiovascular events — only surrogate markers.
Where vitamin K2 disappoints
- Only surrogate markers have moved. Arterial stiffness and MGP activation improve, but no trial has shown MK-7 actually reduces fractures or cardiovascular events — the outcomes people care about are unproven. - The bone data conflict. One 3-year RCT slowed BMD decline; another, equally long, found no BMD benefit in osteopenic women even though the biochemistry clearly worked. Don't expect a guaranteed density gain. - The positive meta-analysis is contaminated. It pools high-dose pharmaceutical MK-4 (Japanese osteoporosis trials) with low-dose MK-7 — so it isn't clean evidence for the 180 µg MK-7 capsule you'd actually take.
Should you start Vitamin K2?
Are you taking warfarin or another vitamin-K-antagonist anticoagulant?
Do not start — K2 antagonizes the drug and can destabilize your INR. Physician clearance required, no exceptions.
node | Do you supplement vitamin D3 or have bone-density / vascular-calcification concerns?
Reasonable to add 180 µg/day MK-7 with a fat-containing meal; recheck relevant biomarkers at 6–12 months
Lower priority — dietary menaquinone (natto, hard cheeses) may be enough; treat MK-7 as optional
On a DOAC, or history of a clotting disorder → physician clearance before starting
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 180 µg/day MK-7 | Trial-anchored — Knapen 2013/2015 both used 180 µg/day |
| Timing | With the largest fat-containing meal | Fat-soluble; absorption depends on dietary fat |
| Form | MK-7 (menaquinone-7), all-trans | Longer half-life than MK-4; MK-4 trials used ~45 mg pharmaceutical doses, not comparable |
| Duration | 6–12 months minimum before judging | Bone and stiffness endpoints move slowly |
Week-one compliance checklist
- [ ] Confirm your product states "MK-7" and an all-trans isomer, not a generic "vitamin K2" blend
- [ ] Pair the dose with your fattiest meal and log it alongside your D3
- [ ] If you take any anticoagulant, stop and get physician clearance before the first dose
Add Vitamin K2 to your stack
K2's clearest rationale is as the partner to vitamin D3 — it helps route the extra calcium D3 mobilizes toward bone and away from arteries.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| dp-ucMGP (inactive matrix Gla protein) | Downward trend | Baseline, 6–12 mo | Flat → verify compliance and that dose is taken with fat |
| Bone mineral density (DXA, spine + hip) | Stable or improved | Baseline, 24 mo | Continued decline → this is consistent with the null osteopenia trial; reassess with physician |
| INR (only if on any anticoagulant) | Per physician | As directed | Any shift → contact prescriber immediately |
← Swipe for more columns →
dp-ucMGP
Elevated (inactive)
dp-ucMGP
Reduced (carboxylated)
Track biomarkers
Log dp-ucMGP if available and schedule a baseline DXA before starting, so a 24-month rescan has something to compare against.
Open Labs hubSafety, red flags, and contraindications
- Generally well tolerated — MK-7 at 180 µg/day has a clean tolerability record across the 3-year trials.
- Fat-soluble — take with food containing fat for meaningful absorption.
Do not self-start without clearance
- Warfarin / vitamin-K-antagonist anticoagulants — K2 directly opposes these drugs and can make anticoagulation unstable and unsafe. Absolute contraindication without physician management.
- DOACs and clotting disorders — even with non-warfarin anticoagulants or a personal/family clotting history, get physician clearance first.
- Not a fracture or heart-attack drug — the human evidence covers surrogate markers (arterial stiffness, BMD, MGP activation), not proven reductions in fractures or cardiovascular events. Do not treat it as a substitute for established therapy.
- Consult a physician before combining with any anticoagulant or antiplatelet regimen.
- Pregnant or nursing individuals should consult a physician before supplementing.
What would change this grade. Vitamin K2 is B on consistent surrogate markers. It would rise to A with a trial showing MK-7 reduces actual fractures or cardiovascular events; it stays capped while the evidence remains biomarker-level and the bone RCTs disagree.
Who should skip vitamin K2
- Anyone on warfarin or another vitamin-K-antagonist anticoagulant — K2 directly opposes the drug and destabilizes INR; absolute contraindication without physician management. - DOAC users or anyone with a clotting-disorder history — get physician clearance first. - Anyone expecting a guaranteed bone-density increase — the trials don't consistently deliver one.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Vitamin D3 | D3 increases calcium absorption and mobilization; K2 helps direct that calcium into bone and away from arteries — the pairing addresses a plausible weakness of D3 monotherapy | Vitamin D3 module |
| Magnesium | Cofactor in bone metabolism and vitamin D activation; rounds out the bone-mineral support triad | Magnesium module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Warfarin / vitamin-K-antagonist anticoagulants | K2 is the direct pharmacological opposite of these drugs | Do not combine without physician INR management — absolute contraindication otherwise |
| — | No other well-characterized supplement antagonists at 180 µg | Co-stacks cleanly, especially with D3 and magnesium |
Personal results template
My Vitamin K2 results log
| Date | Week | Dose | dp-ucMGP | DXA (spine/hip) | Notes |
|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | Baseline (DXA + biomarker) |
| YYYY-MM-DD | 26 | 180 µg | — | — | Mid-point biomarker check |
| YYYY-MM-DD | 104 | 180 µg | — | — | 24-mo DXA rescan |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: dp-ucMGP trending down and DXA stable or improved at 24 months. - Plateau: Biomarker moved but DXA still declining — consistent with the osteopenia null trial; reassess whether K2 is doing anything measurable for you. - Adverse: Any bleeding/clotting change if on an anticoagulant — stop and contact your prescriber.
See the D3 + K2 pairing
K2's strongest case is as D3's calcium-routing partner — see how the two fit together before adding either alone.
Vitamin D3 moduleReferences
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.